Quantitative proteome analysis of ovarian cancer tissues using a iTRAQ approach

Journal of Cellular Biochemistry

Volumn 113, Issue 12, 2012, Pages 3762-3772

  Wang, Li Na ^a,b   Tong, Shi Wen ^a   Hu, Huai Dong ^a   Ye, Feng ^a   Li, Sang Lin ^a   Ren, Hong ^a   Zhang, Da Zhi ^a   Xiang, Rong ^a,b   Yang, Yi Xuan ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b NANKAI UNIVERSITY   (China)

Author keywords

iTRAQ; MASS SPECTROMETRY; OVARIAN CANCER; PROTEOMICS

Indexed keywords

CYTOKERATIN 8; ISOCITRATE DEHYDROGENASE 2; KERATIN TYPE II; PHOSPHATASE; PROTEIN PPA1; PROTEIN S 100; PROTEIN S 100 A11; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; CANCER CELL; CANCER TISSUE; CONTROLLED STUDY; EPITHELIUM; GENE SILENCING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISOBARIC TAGS FOR RELATIVE AND ABSOLUTE QUANTITATION; LIQUID CHROMATOGRAPHY; OVARIAN CANCER TISSUE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; TISSUE MICROARRAY; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL MOVEMENT; CHROMATOGRAPHY, LIQUID; EPITHELIUM; FEMALE; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; KERATIN-8; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROTEOME; PROTEOMICS; REAGENT KITS, DIAGNOSTIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; S100 PROTEINS; STAINING AND LABELING; TANDEM MASS SPECTROMETRY; TISSUE ARRAY ANALYSIS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84867527841     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24250     Document Type: Article

References (45)

1. Banerjee S, Gore M,. 2009. The future of targeted therapies in ovarian cancer. Oncologist 14: 706-716.
2. Bartkowiak K, Wieczorek M, Buck F, Harder S, Moldenhauer J, Effenberger KE, Pantel K, Peter-Katalinic J, Brandt BH,. 2009. Two-dimensional differential gel electrophoresis of a cell line derived from a breast cancer micrometastasis revealed a stem/progenitor cell protein profile. J Proteome Res 8: 2004-2014.
3. Bhide VM, Laschinger CA, Arora PD, Lee W, Hakkinen L, Larjava H, Sodek J, McCulloch CA,. 2005. Collagen phagocytosis by fibroblasts is regulated by decorin. J Biol Chem 280: 23103-23113.
4. Cortesi L, Rossi E, Della Casa L, Barchetti A, Nicoli A, Piana S, Abrate M, La Sala GB, Federico M, Iannone A,. 2011. Protein expression patterns associated with advanced stage ovarian cancer. Electrophoresis 32: 1992-2003.
5. De Luca A, Santra M, Baldi A, Giordano A, Iozzo RV,. 1996. Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J Biol Chem 271: 18961-18965.
6. Donato R,. 2001. S100: A multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 33: 637-668.
7. Fritzsche FR, Dahl E, Pahl S, Burkhardt M, Luo J, Mayordomo E, Gansukh T, Dankof A, Knuechel R, Denkert C, Winzer KJ, Dietel M, Kristiansen G,. 2006. Prognostic relevance of AGR2 expression in breast cancer. Clin Cancer Res 12: 1728-1734.
8. Fritzsche FR, Dahl E, Dankof A, Burkhardt M, Pahl S, Petersen I, Dietel M, Kristiansen G,. 2007. Expression of AGR2 in non small cell lung cancer. Histol Histopathol 22: 703-708.
9. Goldoni S, Seidler DG, Heath J, Fassan M, Baffa R, Thakur ML, Owens RT, McQuillan DJ, Iozzo RV,. 2008. An antimetastatic role for decorin in breast cancer. Am J Pathol 173: 844-855.
10. Gonias SL, Hembrough TA, Sankovic M,. 2001. Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells. Front Biosci 6: D1403-D1411.
11. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R,. 1999. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 17: 994-999.
12. Hembrough TA, Vasudevan J, Allietta MM, Glass WF II, Gonias SL,. 1995. A cytokeratin 8-like protein with plasminogen-binding activity is present on the external surfaces of hepatocytes, HepG2 cells and breast carcinoma cell lines. J Cell Sci 108 (Pt 3): 1071-1082.
13. Hembrough TA, Kralovich KR, Li L, Gonias SL,. 1996. Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation. Biochem J 317 (Pt 3): 763-769.
14. Inada H, Naka M, Tanaka T, Davey GE, Heizmann CW,. 1999. Human S100A11 exhibits differential steady-state RNA levels in various tissues and a distinct subcellular localization. Biochem Biophys Res Commun 263: 135-138.
15. Iozzo RV, Moscatello DK, McQuillan DJ, Eichstetter I,. 1999. Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem 274: 4489-4492.
16. Kim JM, Sohn HY, Yoon SY, Oh JH, Yang JO, Kim JH, Song KS, Rho SM, Yoo HS, Kim YS, Kim JG, Kim NS,. 2005. Identification of gastric cancer-related genes using a cDNA microarray containing novel expressed sequence tags expressed in gastric cancer cells. Clin Cancer Res 11: 473-482.
17. Kovalev LI, Shishkin SS, Khasigov PZ, Dzeranov NK, Kazachenko AV, Kovaleva MA, Toropygin I, Eremina LS, Grachev SV,. 2006. New approaches to molecular diagnosis of prostatic cancer. Urologiia 5: 16-19.
18. Liu F, Chen Z, Wang J, Shao X, Cui Z, Yang C, Zhu Z, Xiong D,. 2008. Overexpression of cell surface cytokeratin 8 in multidrug-resistant MCF-7/MX cells enhances cell adhesion to the extracellular matrix. Neoplasia 10: 1275-1284.
19. Livak KJ, Schmittgen TD,. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408.
20. Makino T, Yamasaki M, Takeno A, Shirakawa M, Miyata H, Takiguchi S, Nakajima K, Fujiwara Y, Nishida T, Matsuura N, Mori M, Doki Y,. 2009. Cytokeratins 18 and 8 are poor prognostic markers in patients with squamous cell carcinoma of the oesophagus. Br J Cancer 101: 1298-1306.
21. Melle C, Ernst G, Schimmel B, Bleul A, Mothes H, Kaufmann R, Settmacher U, Von Eggeling F,. 2006. Different expression of calgizzarin (S100A11) in normal colonic epithelium, adenoma and colorectal carcinoma. Int J Oncol 28: 195-200.
22. Memon AA, Sorensen BS, Meldgaard P, Fokdal L, Thykjaer T, Nexo E,. 2005. Down-regulation of S100C is associated with bladder cancer progression and poor survival. Clin Cancer Res 11: 606-611.
23. Mirgorodskaya OA, Kozmin YP, Titov MI, Korner R, Sonksen CP, Roepstorff P,. 2000. Quantitation of peptides and proteins by matrix-assisted laser desorption/ionization mass spectrometry using (18)O-labeled internal standards. Rapid Commun Mass Spectrom 14: 1226-1232.
24. Mok SC, Chao J, Skates S, Wong K, Yiu GK, Muto MG, Berkowitz RS, Cramer DW,. 2001. Prostasin, a potential serum marker for ovarian cancer: Identification through microarray technology. J Natl Cancer Inst 93: 1458-1464.
25. Nash MA, Deavers MT, Freedman RS,. 2002. The expression of decorin in human ovarian tumors. Clin Cancer Res 8: 1754-1760.
26. Ohuchida K, Mizumoto K, Egami T, Yamaguchi H, Fujii K, Konomi H, Nagai E, Yamaguchi K, Tsuneyoshi M, Tanaka M,. 2006a. S100P is an early developmental marker of pancreatic carcinogenesis. Clin Cancer Res 12: 5411-5416.
27. Ohuchida K, Mizumoto K, Ohhashi S, Yamaguchi H, Konomi H, Nagai E, Yamaguchi K, Tsuneyoshi M, Tanaka M,. 2006b. S100A11, a putative tumor suppressor gene, is overexpressed in pancreatic carcinogenesis. Clin Cancer Res 12: 5417-5422.
28. Oue N, Hamai Y, Mitani Y, Matsumura S, Oshimo Y, Aung PP, Kuraoka K, Nakayama H, Yasui W,. 2004. Gene expression profile of gastric carcinoma: Identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression. Cancer Res 64: 2397-2405.
29. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA,. 2002. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359: 572-577.
30. Pohler E, Craig AL, Cotton J, Lawrie L, Dillon JF, Ross P, Kernohan N, Hupp TR,. 2004. The Barrett's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Mol Cell Proteomics 3: 534-547.
31. Reed CC, Iozzo RV,. 2002. The role of decorin in collagen fibrillogenesis and skin homeostasis. Glycoconj J 19: 249-255.
32. Rehman I, Azzouzi AR, Cross SS, Deloulme JC, Catto JW, Wylde N, Larre S, Champigneuille J, Hamdy FC,. 2004. Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions. Hum Pathol 35: 1385-1391.
33. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, Purkayastha S, Juhasz P, Martin S, Bartlet-Jones M, He F, Jacobson A, Pappin DJ,. 2004. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics MCP 3: 1154-1169.
34. Sakaguchi M, Huh NH,. 2011. S100A11, a dual growth regulator of epidermal keratinocytes. Amino Acids 41: 797-807.
35. Sakaguchi M, Miyazaki M, Takaishi M, Sakaguchi Y, Makino E, Kataoka N, Yamada H, Namba M, Huh NH,. 2003. S100C/A11 is a key mediator of Ca(2+)-induced growth inhibition of human epidermal keratinocytes. J Cell Biol 163: 825-835.
36. Sakaguchi M, Miyazaki M, Sonegawa H, Kashiwagi M, Ohba M, Kuroki T, Namba M, Huh NH,. 2004. PKCalpha mediates TGFbeta-induced growth inhibition of human keratinocytes via phosphorylation of S100C/A11. J Cell Biol 164: 979-984.
37. Sakaguchi M, Sonegawa H, Murata H, Kitazoe M, Futami J, Kataoka K, Yamada H, Huh NH,. 2008. S100A11, an dual mediator for growth regulation of human keratinocytes. Mol Biol Cell 19: 78-85.
38. Seidler DG, Goldoni S, Agnew C, Cardi C, Thakur ML, Owens RT, McQuillan DJ, Iozzo RV,. 2006. Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation. J Biol Chem 281: 26408-26418.
39. Tojo Y, Bandoh S, Fujita J, Kubo A, Ishii T, Fukunaga Y, Ueda Y, Yang Y, Wu F, Huang CL, Yokomise H, Ishida T,. 2003. Aberrant messenger RNA splicing of the cytokeratin 8 in lung cancer. Lung Cancer 42: 153-161.
40. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T,. 2006. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer Phase III Trial. J Clin Oncol 24: 2715-2722.
41. Vanderlaag KE, Hudak S, Bald L, Fayadat-Dilman L, Sathe M, Grein J, Janatpour MJ,. 2010. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin. Breast Cancer Res 12: R32.
42. Wulfkuhle JD, Sgroi DC, Krutzsch H, McLean K, McGarvey K, Knowlton M, Chen S, Shu H, Sahin A, Kurek R, Wallwiener D, Merino MJ, Petricoin EF III, Zhao Y, Steeg PS,. 2002. Proteomics of human breast ductal carcinoma in situ. Cancer Res 62: 6740-6749.
43. Xaus J, Comalada M, Cardo M, Valledor AF, Celada A,. 2001. Decorin inhibits macrophage colony-stimulating factor proliferation of macrophages and enhances cell survival through induction of p27(Kip1) and p21(Waf1). Blood 98: 2124-2133.
44. Yamaguchi Y, Mann DM, Ruoslahti E,. 1990. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 346: 281-284.
45. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC, Jr., Lokshin AE,. 2010. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 28: 2159-2166.